News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
Ohr Pharmaceutical (OHRP) Announces Final Topline Data From OHR-102 Phase II IMPACT Study In Wet-AMD 3/27/2015
Proteon Therapeutics, Inc. (PRTO) Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis 3/27/2015
NIH Release: Ebola Test Vaccines Appear Safe In Phase 2 Liberian Clinical Trial 3/27/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/27/2015
Ohr Pharma (OHRP)'s OHR-102 Fails in Phase II, Shares Plunge 3/27/2015
Burzynski Research Institute Announces Publication Of Phase 2 Clinical Study In Metastatic Colon Adenocarcinoma Of The Liver 3/27/2015
PharmaCyte Biotech (NVLX) On Track to Commence Clinical Trials 3/27/2015
GENFIT (ALGFT) Announces Topline Results From The Golden-505 Trial In Nash 3/26/2015
Conatus Pharma Shares Soar On Successful Emricasan Phase II Results 3/26/2015
Otonomy, Inc. (OTIC) Initiates Phase 2 Clinical Trial for AuriPro(TM) In Label Expansion Indication 3/26/2015
Galena Biopharma  (GALE) Expands Patient Population In NeuVax(TM) (nelipepimut-S) And Trastuzumab Phase 2b Combination Clinical Trial In HER2 1+/2+ Patients 3/26/2015
Conatus Pharmaceuticals Inc. Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial Of Emricasan 3/26/2015
Aldeyra Therapeutics (ALDX) Opens Enrollment In Noninfectious Anterior Uveitis Phase II Clinical Trial 3/26/2015
Apceth GmbH Initiates Phase II Clinical Trial For Pioneering Engineered Cell Therapy To Treat Gastrointestinal Cancer 3/26/2015
Amarantus BioSciences, Inc. Opens Investigational New Drug (IND) Application With The U.S. FDA Allowing The Start Of A Phase 2b Program Of Eltoprazine In Parkinson's Disease Levodopa-Induced Dyskinesia 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Dermira Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results 3/26/2015
CASI Pharmaceuticals  (CASI) Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3/25/2015
Agios Pharmaceuticals (AGIO) Announces Orphan Drug Designation Of AG-348 For Treatment Of Pyruvate Kinase Deficiency 3/25/2015
Lpath, Inc. (LPTN) Reports Results For ASONEP Phase 2a Study In Renal Cell Carcinoma 3/25/2015
Signum Dermalogix Out-Licenses SIG990 To Dermata Therapeutics For Topical Treatment of Rosacea 3/25/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
VBL Therapeutics (VBLX) Reports Interim Topline Results From Phase 2 Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm) 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Interim Results From Phase IIb Clinical Trial For Knee Osteoarthritis Stem Cell Rejoin Therapy 3/25/2015
Marinus Pharmaceuticals (MRNS)' Ganaxolone Receives FDA Orphan Drug Designation In PCDH19 Female Epilepsy 3/25/2015
TRANSGENE (ENX:TNG) Reports 2014 Financial Results And Outlines Promising Clinical Pipeline 3/25/2015
Mologen AG (MOLGF.PK): Start Of Pivotal Study For Cancer Immunotherapy MGN1703 Influences 2014 Annual Result 3/25/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Status From The European Medicines Agency For Ovarian Cancer 3/25/2015
Why Investors Shouldn't Freak Out Over Vertex (VRTX)'s Latest Trial Results 3/24/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Sjogren-Larsson Syndrome Phase II Clinical Trial 3/24/2015
NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine 3/24/2015
Pluristem Therapeutics (PSTI) Announces Key Strategic Objectives For Development Of PLX-R18 In Hematopoietic Indications 3/24/2015
MediGene AG (MDGEF.PK) Starts Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 3/24/2015
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented During Plenary Presentations At The 2015 European Association Of Urology Congress 3/24/2015
Soligenix (SNGX) Announces Recent Accomplishments And Year-End 2014 Financial Results 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/24/2015
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Announces Top-Line Data From Randomized Phase II Clinical Study Of Pracinostat In Front-Line Myelodysplastic Syndrome 3/23/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
GenVec Inc. (GNVC) And TheraBiologics Form Collaboration To Develop Neural Stem Cell Mediated Cancer Therapies 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Mast Therapeutics (MSTX) To Develop Vepoloxamer (MST-188) In Chronic Heart Failure 3/23/2015
Anavex (AVXL) Presents Positive Results For Both ANAVEX 2-73 And ANAVEX 3-71 In Alzheimer's Models At 2015 AD/PD Conference 3/23/2015
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015 3/23/2015
Lpath, Inc. (LPTN) To Hold Investor Update Conference Call 3/23/2015
Clinical Data For Dermira's DRM01 Acne Program Presented At Dermatology Meeting 3/23/2015
Teva (TEVA)'s TEV-48125 Meets Primary And Secondary Endpoints In Episodic Migraine Study, Demonstrating Treatment Concept After A Single Dose 3/23/2015
Vertex (VRTX) Announces Data From 12-Week Phase 2 Safety Study Of VX-661 In Combination With Ivacaftor In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 3/23/2015
Bone Therapeutics Treats First Patients In ALLOB Phase IIA Spinal Fusion Trial 3/23/2015
Intercept Pharmaceuticals (ICPT) Announces New Data Analyses From FLINT Trial Of Obeticholic Acid In NASH 3/20/2015
Dilaforette Receives Orphan Drug Designation In The U.S. For Sevuparin In Sickle-Cell Disease 3/20/2015
Cerulean Pharma Inc. (CERU) Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin In Relapsed Renal Cell Carcinoma Meets Primary Endpoint 3/20/2015
Boehringer Ingelheim Pharmaceuticals, Inc.'s Investigational Biologic Cleared Skin Better Than Ustekinumab In Head-To-Head Phase II Psoriasis Study 3/20/2015
Dignity Sciences Presents Late-Breaking News Abstract On DS107 At American Academy of Dermatology Annual Meeting 3/20/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Manufacturing Agreement With Pharmacell B.V. For European Production Of ICT-107 For Phase 3 Registration Trial 3/19/2015
PTC Therapeutics (PTCT) And University of Pennsylvania Collaborate On Orphan Disease Research 3/19/2015
Phase II Data For Celgene (CELG)’s Investigational Oral GED-0301 For Patients With Active Crohn’s Disease Published In New England Journal Of Medicine 3/19/2015
BioInvent (BOVNF) Confirms Clinical Strategy For BI-505 And Plans To Conduct Phase IIa Trial In Multiple Myeloma Post-Stem Cell Transplant Patients In The U.S. 3/19/2015
Hemostemix Expands Clinical Trial For Critical Limb Ischemia (CLI) To Four Sites In South Africa, Treats First South African Participant 3/19/2015
Threshold Pharmaceuticals, Inc. (THLD) To Present Data Supporting Planned Phase 2 Trials Of TH-4000, A Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor 3/19/2015
Creabilis' CT327 Phase 2b Data Published In Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA For The Treatment Of Pulmonary Arterial Hypertension 3/18/2015
BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution 3/18/2015
Can-Fite BioPharma (CFBI) Completes Development Of Commercial Biomarker Test To Predict Patients' Response To Company Drugs 3/18/2015
Ascletis, Inc. Reports Strong Phase II Data For Hepatitis C Drug 3/18/2015
Novan Therapeutics Achieves Target Enrollment For Phase 2 Acne Study 3/18/2015
Allena Pharmaceuticals, Inc. Announces Positive Phase IIa Data Of ALLN-177 For The Treatment Of Hyperoxaluria 3/18/2015
La Jolla Pharmaceutical Company (LJPC) Announces Initiation Of Phase 2b Clinical Trial Of GCS-100 In Advanced Chronic Kidney Disease 3/18/2015
Imperial Innovations' Cell Medica Granted Orphan Drug Designation For Novel Cellular Therapy And Treats First Lymphoma Patient In CITADEL Phase II Trial 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Here's Why Investors are Already Anticipating Vertex (VRTX) Trial Data Coming This Month 3/17/2015
Kindred Bio (KIN) Announces Positive Results Of Pilot Field Study Of KIND-012 For The Control Of Fever In Horses 3/17/2015
Ablynx (ABLYF) Initiates The First Of Two Phase IIb Ra Studies With Its Anti-Il-6R Nanobody, Partnered With AbbVie (ABBV) 3/17/2015
Cellerant Therapeutics, Inc. Announces Dosing Of First Patient In Randomized Phase 2 Clinical Trial Of CLT-008 In Acute Myeloid Leukemia Patients 3/17/2015
Aldeyra Therapeutics (ALDX) Opens Enrollment In Sjogren-Larsson Syndrome Clinical Trial And Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol 3/17/2015
Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer's Disease 3/17/2015
Ocata Therapeutics Receives Regulatory Guidance From European Medicines Agency 3/17/2015
Aclaris Therapeutics' Lead Drug Candidate A-101 Achieves Statistically Significant Results In Third Phase 2 Clinical Trial For Seborrheic Keratosis, A Common Type Of Benign Skin Tumor 3/17/2015
Esperion Therapeutics (ESPR) Announces Positive Top-Line Phase 2b Results For ETC-1002 Added To Stable Statin Therapy In Patients With Hypercholesterolemia 3/17/2015
ARCA biopharma Provides GENETIC-AF Clinical Trial Update 3/17/2015
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis 3/16/2015
Amgen (AMGN) Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha (evolocumab) In The The New England Journal of Medicine 3/16/2015
NovImmune SA Release: New Drug Begins Testing As First-Line Treatment For Fatal Childhood Disease 3/16/2015
Relypsa, Inc. (RLYP) Announces Phase II Data Showing Efficacy Of Patiromer FOS In Heart Failure Patients With Chronic Kidney Disease At American College of Cardiology Scientific Session 3/16/2015
NeoStem, Inc. Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results 3/16/2015
New Data From Boehringer Ingelheim Pharmaceuticals, Inc.'s GLORIA-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients At High Risk Of Stroke May Be Undertreated 3/16/2015
VAXIL Receives EU Orphan Drug Designation For Immucin For The Treatment Of Multiple Myeloma 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Synthetic Biologics Reports Year End 2014 Financial Results And Operational Highlights 3/16/2015
NeuralStem Inc. Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results 3/16/2015
Stealth BioTherapeutics Announces EMBRACE Results: A Phase II Clinical Study Of Bendavia In Acute Coronary Syndrome 3/16/2015
Clearside Biomedical Reports Efficacy And Safety Results In Non-Infectious Uveitis Using A Single Suprachoroidal Injection Of Triamcinolone Acetonide 3/16/2015
Alnylam (ALNY) Presents Results From Natural History Study Of Patients With Familial Amyloidotic Cardiomyopathy (FAC) And Presents Complete Results From Phase II Clinical Trial For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of FAC 3/16/2015
Akebia Therapeutics, Inc. (AKBA) Announces Presentation Of Results From Its Phase IIb Study Of AKB-6548 In Non-Dialysis Patients With Anemia Related To Chronic Kidney Disease At International Society of Nephrology’s World Congress Of Nephrology 3/16/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
AB Science (AB.PA) : Positive Phase II Clinical Study Data Of Masitinib In Triple Negative Breast Cancer 3/13/2015
Theravance Biopharma Announces Initiation Of Phase 2b Study Of Velusetrag (TD-5108) For The Treatment Of Gastroparesis 3/13/2015
BioSpecifics Technologies Corporation (BSTC) Reports Fourth Quarter And Full Year 2014 Financial Results 3/13/2015
EXCLUSIVE: AgeneBio CEO Says Delays in Alzheimer's Onset Could Save Millions, As Paradigm Shifts 3/12/2015
NeuralStem Inc. Announces Topline Results Of Phase II ALS Trial 3/12/2015
Annias Immunotherapeutics, Inc. Release: Dramatic Patient Survival Benefit Shown For New Approach To Treating Glioblastoma Multiforme Licensed To Annias Immunotherapeutics 3/12/2015
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Elafin Combined With Cyclosporine Promises To Overcome Limitations Of Cyclosporine For Preventing Irreversible Damage To Transplanted Organs 3/12/2015
Cynapsus Therapeutics (CYNAF) Provides Clinical And Regulatory Update For APL-130277 For The Acute Rescue Of OFF Motor Symptoms Of Parkinson’s Disease 3/12/2015
Ember Therapeutics And Mariel Therapeutics Enter Definitive Merger Agreement Creating A Strong Diversified Company 3/12/2015
Galectin Therapeutics Engages PPD, Inc. (PPDI) To Conduct GR-MD-02 Phase 2 Trial In NASH, Submits Special Protocol Assessment To FDA 3/12/2015
AgeneBio Announces Publication Of Phase 2 Clinical Trial Results For New Approach To Delaying The Onset Of Alzheimer's Dementia 3/11/2015
Daktari Awarded NIH SBIR Phase II For Its Hepatitis C Diagnostic 3/11/2015
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial 3/11/2015
Herantis Pharma's Phase 2 Dry Eye Study Recruitment Completed Ahead Of Schedule 3/11/2015
Gynecologic Oncology Group Commences Enrollment In Stage 2 Of GOG-0265 Clinical Trial 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Tekmira (TKMR)-Ebola-Guinea Enters Phase II Clinical Study In Sierra Leone 3/11/2015
Alcobra (ADHD)'s MDX Meets Primary Endpoint In Phase II Safety And Tolerability Clinical Trial In Adolescents With ADHD 3/10/2015
Puma Biotechnology (PBYI) Initiates Phase II Trial Of PB272 In Early Stage HER2-Positive Breast Cancer 3/10/2015
Madison Vaccines Announces Program Expansions For Its Investigational Prostate Cancer Vaccines 3/10/2015
CardioCell Adds Stony Brook University To Sites Conducting A Phase Ila Clinical Trial Using Its Stem Cells FOR Patients With Chronic Heart Failure 3/10/2015
Viamet Pharmaceuticals Announces Initiation Of RENOVATE Phase 2b Study Of Oral VT-1161 In Onychomycosis 3/10/2015
Akebia Therapeutics, Inc. (AKBA) Announces Completion Of Enrollment In Phase 2 Trial Of AKB-6548 In Dialysis Patients With Anemia Related To Chronic Kidney Disease 3/10/2015
Zafgen (ZFGN) Announces New Weight Loss And Safety Data From Phase II Trial Of Beloranib In Hypothalamic Injury Associated Obesity At ENDO 2015 3/9/2015
Galmed Pharmaceuticals Announces The Beginning Of Enrollment In Its Phase IIb ARREST Trial For The Treatment Of NASH, As Well As The Expansion Of The Study To The United States 3/9/2015
Ultragenyx Pharmaceuticals (RARE) Announces Presentation Of Disease Burden Data In Adult Patients With X-Linked Hypophosphatemia 3/9/2015
Esperion Therapeutics (ESPR) Release: ETC-1002-008 Phase 2b Results To Be Presented At American College of Cardiology 64th Annual Scientific Session 3/9/2015
ORYX Successfully Completes Phase 1/2a Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers 3/9/2015
Probiodrug AG Announces Enrolment Of First Patient In Phase 2 Study Of Novel Treatment For Alzheimer’s Disease 3/9/2015
Trevena, Inc. (TRVN) Completes Interim Analysis And Announces Plans For Ongoing Phase 2b BLAST-AHF Trial Of TRV027 In Acute Heart Failure 3/9/2015
Corbus Pharmaceuticals, Inc.' IND Receives Clearance From FDA To Initiate Phase 2 Trials In Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab 3/9/2015
Hua Medicine Files To Start U.S. Trial Of Novel Diabetes Drug 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
AVEO Oncology (AVEO) Announces Presentation Of Phase 2 Study Analysis Showing Longer PFS With Tivozanib Compared To Bevacizumab In Low Serum NRP-1 Patients With Advanced CRC 3/6/2015
Hemostemix Expands Clinical Trial For Treating Critical Limb Ischemia To The Peter Munk Cardiac Centre At Toronto General Hospital 3/6/2015
ViroMed Co., Ltd. dba VM BioPharma: A Phase 2 Study Done At Northwestern Hospital Shows Potential Relief For Diabetics With Painful Condition 3/6/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
XBiotech USA, Inc. Announces Phase II Psoriasis Study Results in JAMA Dermatology 3/5/2015
Asterias Biotherapeutics Initiates Patient Enrollment For Phase 1/2a Clinical Trial Of AST-OPC1 In Newly Injured People With Complete Cervical Spinal Cord Injury 3/5/2015
Vanda Pharmaceuticals, Inc. (VNDA) Announces Tradipitant Phase II Proof Of Concept Study Results For Chronic Pruritus In Atopic Dermatitis 3/5/2015
Capricor Therapeutics, Inc. Announces Enrollment Of Its Phase II Clinical Trial For Cenderitide To Treat Heart Failure 3/5/2015
PlasmaTech Biopharmaceuticals' Announces Initiation Of Enrollment Of MuGard Trial For Afinitor (Everolimus; Novartis) - Related Stomatitis At University of California, Los Angeles (UCLA) Breast Cancer Center 3/5/2015
New Jersey Startup Celimmune Aims to Give New Life to Shelved Amgen (AMGN) Drug 3/4/2015
Pharma Two B Completes Enrollment In Phase IIb Study Of P2B001 For Parkinson's Disease 3/4/2015
Receptos (RCPT) Provides Development Updates And Reports Fourth Quarter And Year End 2014 Financial Results 3/4/2015
Resverlogix Corporation (RVX.TO) Collaborates With Emerald Logic To Identify Factors Driving Drug Response And Efficacy In Phase 2 Program 3/4/2015
ORYX' Therapeutic Vaccine Micoryx Successfully Completes Phase 1/2a Trial To Treat MSH-H Colorectal Cancer 3/4/2015
Soligenix (SNGX) Announces Positive Recommendation By Data Review Committee On Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 3/3/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Aquinox Pharmaceuticals (AQXP) Completes Enrollment In The Phase II LEADERSHIP Trial Of AQX-1125 In Bladder Pain Syndrome/Interstitial Cystitis 3/3/2015
Biota Pharmaceuticals, Inc. (BOTA) Commences Dosing In Vapendavir SPIRITUS Phase IIb Trial 3/3/2015
DURECT Corporation (DRRX) Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development 3/3/2015
MediciNova, Inc. Release: MN-166 (Ibudilast) Effects In Opioid Dependence Selected For Presentation At The 77th Annual Meeting Of The College On Problems Of Drug Dependence In Phoenix, Arizona 3/3/2015
Amgen (AMGN) Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3/3/2015
Prima Biomed (PRR.AX) To Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3 3/3/2015
Opko Health, Inc. (OPK) Release: Twelve Months Data Supporting Once-Weekly Dosing Of Hgh-CTP In Growth Hormone Deficient Pediatric Population To Be Presented At ENDO 2015 Conference 3/3/2015
GlycoMimetics, Inc. (GLYC) Announces Publication Of Phase 2 Data For Rivipansel In Sickle Cell Disease 3/3/2015
Vince & Associates Clinical Research Completes CymaBay Therapeutics’ Clinical Trial Of Arhalofenate In Combination With Febuxostat 3/3/2015
Melior Pharmaceuticals Initiates Phase 2 Study With MLR-1023 For Type 2 Diabetes 3/3/2015
Transition Therapeutics Inc. (TTH.TO) Announces Enrolment Completion Of ELND005 Phase 2 Clinical Study In Agitation And Aggression In Patients With Alzheimer's Disease 3/2/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Cancer Of The Fallopian Tube 3/2/2015
Acasti Pharma Receives Full Data For Phase II TRIFECTA Trial 3/2/2015
Aldeyra Therapeutics (ALDX) Provides Update On NS2 Clinical Program 3/2/2015
Ohr Pharmaceutical (OHRP) Announces Additional Positive Anatomic Data From The OHR-102 IMPACT Study Interim Analysis Presented At Annual Macula Society Meeting 3/2/2015
Acceleron Pharma Presents Encouraging Response Rates And Progression-Free Survival Data In Patients With Advanced Renal Cell Carcinoma At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium 3/2/2015
Alizé Pharma Launches Phase 2 Clinical Trial Of AZP-531 In Prader-Willi Syndrome 3/2/2015
BioLineRx Ltd. Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment 3/2/2015
Opsona Therapeutics Ltd. Commences Part B Of Phase II Study Of Blocking Toll-Like Receptor 2 In Extended Criteria Donor Renal Transplant Recipients At High Risk Of Early Graft Dysfunction 3/2/2015
Clearside Biomedical Initiates Phase 2 Clinical Trial To Evaluate Reducing Treatment Visits While Improving Outcomes In Macular Edema Associated With Retinal Vein Occlusion 3/2/2015
Isis Pharmaceuticals, Inc. (ISIS) Earns $15 Million From GlaxoSmithKline (GSK) for Advancing ISIS-TTR Rx 3/2/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Phosphate Therapeutics Announces Completion Of Subject Recruitment Into The PEACH Pivotal Phase 2 Study Of Its Novel Phosphate Binder (PT20) For The Treatment Of Hyperphosphataemia 2/26/2015
Sangamo BioSciences (SGMO) Presents New Clinical Data At CROI 2015 From Trial Of ZFP Therapeutic Designed To Provide Functional Control Of HIV 2/26/2015
Columbia Laboratories, Inc. (CBRX) To Initiate A Phase 2 Clinical Trial For COL-1077, Lidocaine Bioadhesive 10% Gel, In The Second Quarter Of 2015 2/26/2015
Progenics Pharmaceuticals, Inc. (PGNX) Presents Positive Phase 2 Data For PSMA ADC In Metastatic Castration-Resistant Prostate Cancer 2/26/2015
Aduro Biotech Collaborates With Leaders In Cancer Research On Investigator-Sponsored Phase 2 Trial Combining Aduro’s Innovative Immunotherapies With Anti-PD-1 Technology To Treat Patients With Advanced Pancreatic Cancer 2/26/2015
Afferent Corporation Clinical Data For Lead Candidate, AF-219, Demonstrate Improvements In Pain And Urinary Urgency In Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) 2/26/2015
ISA Pharmaceuticals Announces Start Of First Phase 1/2 Clinical Trial Of Its SLP®-AMPLIVANT® Conjugates 2/26/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
Pfizer (PFE)'s Meningitis B Vaccine Meets Safety, Tolerability Goals in Mid-Stage Study 2/25/2015
MicuRx Pharmaceuticals Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 2/25/2015
Valeant (VRX) Release: PROVENGE (sipuleucel-T) Demonstrates Sustained Immune Response Two Years After Treatment In Biochemically-Recurrent Prostate Cancer 2/25/2015
Dilafor Announces Positive Results From A Multi Dosing Safety And Pharmacokinetic Clinical Study 2/25/2015
Celldex (CLDX)'s Rindopepimut Deemed a Breakthrough By the FDA 2/24/2015
Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study Of Bryostatin-1 In Alzheimer's Disease 2/24/2015
Progenics Pharmaceuticals, Inc. (PGNX) To Present Full Phase 2 Data For PSMA ADC At The 2015 American Society of Clinical Oncology GU Symposium 2/24/2015
Flexion Therapeutics (FLXN) Completes Enrollment In Pivotal Phase 2b Confirmatory Clinical Trial With Lead Compound FX006 2/24/2015
Galectin Therapeutics Announces Details Of The Design Of Its Phase 2 Program With GR-MD-02 2/24/2015
OncoGenex Pharmaceuticals Inc. (OGXI) And Sarah Cannon Research Institute Announce Completion Of Patient Enrollment In The Spruce Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer 2/24/2015
Teva Pharmaceutical Industries (TEVA) Announces Positive Results For TEV-48125 In Phase IIb Chronic Migraine Study Meeting Primary And Secondary Endpoints 2/24/2015
Celldex (CLDX)'s Rindopepimut (Rintega) Receives FDA Breakthrough Therapy Designation For The Treatment Of Adult Patients With Egfrviii-Positive Glioblastoma 2/23/2015
ContraVir Pharmaceuticals Provides Clinical Update On FV-100 2/23/2015
Savara's AeroVanc Meets Primary Endpoint Of MRSA Reduction In Phase 2 Trial In People With Cystic Fibrosis 2/23/2015
Boehringer Ingelheim Corporation Release: New Phase 2 Data In Asthma Patients Show Tiotropium Improves Lung Function, Regardless Of Allergic Status 2/23/2015
Eiger Biopharma Announces Presentation Of Positive Data In Patients Infected With Hepatitis Delta Virus (HDV) Treated With Lonafarnib 2/23/2015
Emisphere Technologies, Inc. (EMIS) Highlights Positive Phase 2 Og217sc Data From Eligen Licensee Novo Nordisk A/S (NVO) 2/23/2015
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015
NovoCure Ltd. Enrolls The First Patient In Its Phase II STELLAR Trial Of Tumor Treating Fields Together With Pemetrexed And Cisplatin Or Carboplatin For The Treatment Of Malignant Mesothelioma 2/23/2015
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015
Galapagos NV (GLPG.BR) Reports That The Last Patient In Darwin 1 Has Completed 12 Weeks Of Treatment 2/23/2015